These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 2389483)

  • 1. High rate of success in kidney cadaveric retransplantation with optimal matching and potent immunosuppression.
    Hiesse C; Neyrat N; Busson M; Bensadoun H; Lantz O; Bellamy J; Benoit G; Charpentier B; Fries D
    Transplant Proc; 1990 Aug; 22(4):1909-10. PubMed ID: 2389483
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of DR and DR6 matching on cadaver kidney transplant survival.
    Reyman TA; Toledo-Pereyra LH
    Transplant Proc; 1987 Feb; 19(1 Pt 1):702-4. PubMed ID: 3274848
    [No Abstract]   [Full Text] [Related]  

  • 3. Beneficial effects of some donor-recipient HLA-DR mismatches on cadaveric graft survival: proposal for a new selection policy of recipients.
    Vereerstraeten P; Andrien M; De Pauw L; Dupont E; Goldman M; Abramowicz D; Kinnaert P
    Transplant Proc; 1991 Feb; 23(1 Pt 1):385-6. PubMed ID: 1990560
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerance induction in human kidney retransplantation: impact of repeated HLA mismatches in 156 second renal grafts.
    Gnant MF; Sautner T; Rosenmayr A; Muehlbacher F
    Transplant Proc; 1993 Feb; 25(1 Pt 1):319-21. PubMed ID: 8438317
    [No Abstract]   [Full Text] [Related]  

  • 5. Cadaveric renal transplantation after pulsatile perfusion, histocompatibility matching, and conversion to cyclosporine therapy.
    Milgrom M; Kyriakides GK; Esquenazi V; Olson L; Miller J
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1873. PubMed ID: 3274444
    [No Abstract]   [Full Text] [Related]  

  • 6. Potent immunosuppression overcomes retransplantation, presensitization, and historical positive crossmatch as transplant risk factors.
    Gaber AO; Thistlethwaite JR; Haag BW; Stuart J; Mayes J; Fellner S; Stuart FP
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1915-6. PubMed ID: 3274451
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients.
    Opelz G; Schwarz V; Engelmann A; Back D; Wilk M; Keppel E
    Transplant Proc; 1991 Feb; 23(1 Pt 1):373-5. PubMed ID: 1990556
    [No Abstract]   [Full Text] [Related]  

  • 8. Critical importance of HLA antigen matching in cadaveric kidney transplantation with high overall survival rates. The Manchester UK Kidney Transplant Team.
    Dyer PA; Martin S; Johnson RW
    Transplant Proc; 1992 Dec; 24(6):2454. PubMed ID: 1465827
    [No Abstract]   [Full Text] [Related]  

  • 9. Quadruple therapy for cadaver renal transplantation.
    Deierhoi MH; Sollinger HW; Kalayoglu M; Belzer FO
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1917-9. PubMed ID: 3274452
    [No Abstract]   [Full Text] [Related]  

  • 10. Cadaveric kidney transplantation in patients with lymphocytotoxic autoantibodies.
    Emonds MP; Dendievel J; Roels L; Waer M; Vanrenterghem Y; Vermylen C
    Transplant Proc; 1992 Dec; 24(6):2502-3. PubMed ID: 1465845
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of HLA matching supersedes many others for long-term cadaver kidney transplants.
    Milgrom M; Gomez C; Esquenazi V; Olson L; Roth D; Miller J
    Transplant Proc; 1989 Feb; 21(1 Pt 1):675-6. PubMed ID: 2650218
    [No Abstract]   [Full Text] [Related]  

  • 12. Early or delayed use of cyclosporine in HLA-mismatched living-related donor renal transplants.
    Sumrani N; Hong JH; Daskalakis P; Cacciarelli TV; Markell MS; Sommer BG
    Transplant Proc; 1993 Jun; 25(3):2246-7. PubMed ID: 8516888
    [No Abstract]   [Full Text] [Related]  

  • 13. The improving prognosis after kidney transplantation. New strategies to overcome immunologic rejection.
    Levey AS
    Arch Intern Med; 1984 Dec; 144(12):2382-7. PubMed ID: 6391406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minnesota experience with 81 pancreas transplants since 1978.
    Sutherland DE; Chinn PL; Goetz FC; Elick BA; Najarian JS
    Transplant Proc; 1984 Jun; 16(3):695-703. PubMed ID: 6375036
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
    Giral M; Taddei C; Nguyen JM; Dantal J; Hourmant M; Cantarovich D; Blancho G; Ancelet D; Soulillou JP
    Clin Transpl; 1996; ():257-64. PubMed ID: 9286575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcome of repeat cadaveric kidney transplants in recipients managed with cyclosporine.
    Smith AY; Van Buren CT; Lewis RM; Kerman RH; Welsh M; Kahan BD
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):180-93. PubMed ID: 3291239
    [No Abstract]   [Full Text] [Related]  

  • 18. Collaborative Transplant Study--10-year report.
    Opelz G
    Transplant Proc; 1992 Dec; 24(6):2342-55. PubMed ID: 1465795
    [No Abstract]   [Full Text] [Related]  

  • 19. Is sequential low-dose immunotherapy the preferred treatment in cadaveric renal transplantation?
    Posner MP; Mendez-Picon G; King A; Nelson KP; Spicer HG; Lee HM
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1594-7. PubMed ID: 2652519
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategy for improving retransplantation in the CyA era.
    Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK
    Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.